Gilead Sciences Gets CRL From FDA For Investigational Lenacapavir Due To Vial Compatability Issues
1/3 15:00
(RTTNews) - Gilead Sciences Inc. (GILD) said it has received a complete response letter from the U.S. Food and Drug Administration for Investigational Lenacapavir, citing issues related to compatibility of vials and lenacapavir solution. The FDA did not ask new clinical studies i...